Allogeneic CAR T-cell therapies are very promising. They remain promising. I think that we’re still seeing data from the key clinical trials, testing out allogeneic CAR T-cell therapy in large B-cell lymphoma. There’s two abstracts being presented here, at the ASH annual meeting, abstract 649, which is looking at the ALPHA-2 study, which I’m involved in, testing out allogeneic CD19-directed CAR T-cell therapy in patients with lymphomas...
Allogeneic CAR T-cell therapies are very promising. They remain promising. I think that we’re still seeing data from the key clinical trials, testing out allogeneic CAR T-cell therapy in large B-cell lymphoma. There’s two abstracts being presented here, at the ASH annual meeting, abstract 649, which is looking at the ALPHA-2 study, which I’m involved in, testing out allogeneic CD19-directed CAR T-cell therapy in patients with lymphomas.
Similarly, abstract 650 is giving some preliminary results from the Precision BioSciences CD19-directed CAR T-cell therapy. And so, we’ll see what those data show. But I think there’s clearly a path towards these therapies becoming commercially available, where they can be used for patients. They offer some potential advantages, quickly get them off-the-shelf and treat the patient right away, which we can’t do with autologous CAR T-cell therapies. But we need more data. We need more patients to be treated. But I’m very encouraged by the results, and hopeful that we’ll get these therapies approved for use as a standard of care